Elezanumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameElezanumab
Drug Alias NameABT-555
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionRepulsive guidance molecule A inhibitorsImmunomodulatorsMyelin proteins stimulants
TargetsRepulsive guidance molecule AMyelin proteins
Therapy Area/IndicationsIschemic StrokeSpinal Cord InjuriesMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsIschemic StrokeSpinal Cord InjuriesMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A